(AOF) – Adocia displays a cash position of 13 million euros as of December 31, 2023, compared to 17.4 million euros as of December 31, 2022, with a cash consumption of 3.8 million euros on the fourth quarter, lower than last year (23 million euros), on a comparable basis. This clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity estimates that it will be able to finance its activities until the end of August 2024.
“We are coming out of an eventful 2023 with a strengthened company and we are approaching 2024 with active discussions with Sanofi on M1Pram, but also with key players on AdoShell Islets,” declares Olivier Soula, CEO and co-founder of Adocia . The latter evokes “innovations with high added value which are today arousing the interest of the largest pharmaceutical laboratories”. “We are preparing to make 2024 a transformative year for Adocia.”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
